{
  "item1": "directly operate approximately 100 countries outside United States through wholly-owned subsidiaries or, some cases, through joint venture local partner. certain countries, selected products sold export operations distributors, agents licensees, although volume those sales not significant terms overall revenues. general, businesses conducted outside United States similar those conducted United States. business operations outside United States subject usual risks foreign operations, including possible changes trade foreign investment laws, international business laws regulations, tax laws, currency exchange rates economic political conditions.",
  "item7": "CRITICAL ACCOUNTING ESTIMATES consolidated financial statements prepared accordance U.S. GAAP. adopted various accounting policies prepare consolidated financial statements accordance U.S. GAAP.",
  "item2": "Public currency operating income change Percentages above table do not necessarily sum due rounding. Fixed currency organic sales Global Life Sciences increased 6% 5% third quarter first nine months 2025, respectively, driven new business wins progressively improving industry trends. Continued growth bioprocessing pharmaceutical & personal care overcame ongoing capacity constraints within Life Sciencesâ€™ industrial water purification business. Organic operating income organic operating income margins increased third quarter first nine months 2025 Global Life Sciences segment."
}